AlzeCure gives live streamed strategy update on Alzheimer’s disease and NeuroRestore on September 1
Stockholm, Sweden, August 17, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that it will give a live streamed update focusing on its project platform NeuroRestore and Alzheimer’s disease on September 1 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Fredrik Thor, analyst at Redeye.Martin Jönsson, CEO at AlzeCure, together with Johan Sandin, CSO, and Pontus